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opMen with prostate cancer face difﬁcult choices when selecting a therapy for localized prostate cancer.
Comparative data from controlled studies are lacking and clinical opinions diverge about the
beneﬁts and harms of treatment options. Consequently, there is limited guidance for patients
regarding the impact of treatment decisions on quality of life. There are opportunities for public
health to intervene at several decision-making points. Information on typical quality of life outcomes
associated with speciﬁc prostate cancer treatments could help patients select treatment options.
From 2003 to present, the Division of Cancer Prevention and Control at CDC has supported
projects to explore patient information-seeking behavior post-diagnosis, caregiver and provider
involvement in treatment decision making, and patient quality of life following prostate cancer
treatment. CDC’s work also includes research that explores barriers and facilitators to the
presentation of active surveillance as a viable treatment option and promotes equal access to
information for men and their caregivers. This article provides an overview of the literature and
considerations that initiated establishing a prospective public health research agenda around
treatment decision making. Insights gathered from CDC-supported studies are poised to enhance
understanding of the process of shared decision making and the inﬂuence of patient, caregiver, and
provider preferences on the selection of treatment choices. These ﬁndings provide guidance about
attributes that maximize patient experiences in survivorship, including optimal quality of life and
patient and caregiver satisfaction with information, treatment decisions, and subsequent care.
(Am J Prev Med 2015;49(6S5):S483–S488) Published by Elsevier Inc. on behalf of American Journal of
Preventive Medicine. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).IntroductionMore than 200,000 men are diagnosed withprostate cancer annually,1 the majority diag-nosed with localized disease.2,3 Treatment
choices available to newly diagnosed, early-stage prostate
cancer patients include radical prostatectomy; brachy-
therapy; external beam radiation; and active surveillance
(AS).3 Most of these treatments can affect health-related
quality of life (QOL)3 as a result of signiﬁcant morbidity
and physical side effects. However, AS may be associated
with increased anxiety, missed opportunity for cure, risk
of progression or metastasis, more complex subsequent
treatment, frequent medical exams, and periodic biopsies
that may result in complications.4emiology and Applied Research Branch, Division of Cancer
d Control, National Center for Chronic Disease Prevention
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treatment and their potential side effects, new patients
may experience difﬁculty deciding what treatment is best
suited for their cancer, personal preferences and health
status, and home support environment, and information
on typical QOL outcomes associated with prostate cancer
treatments could guide patients in selecting treatment
options. For many men, treatment discussions and
decisions may take place at home with family.5 Treat-
ment choices are inevitably inﬂuenced by three decision
makers: the patient; the physician; and (when present)
the patient’s family (e.g., spouse/partner or caregiver).6 In
2003, there were no known published prospective studies
that examined the inﬂuence of this triad of decision
makers on treatment decisions or prospectively explored
how knowledge, preferences, and interactions among
prostate cancer patients, caregivers, and treating physi-
cians ultimately inﬂuence treatment choice, QOL, and
treatment satisfaction.
In 2003, CDC supported two Prevention Research
Centers (University ofWashington and Emory University)e Medicine.
//creativecommons.org/licenses/by-nc-nd/4.0/).
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treatment, caregiver involvement, and patient, caregiver,
and physician perceptions of patient QOL. These studies
focused on information-seeking behavior, how treatment
decisions are made, and patient-reported QOL 12
months following diagnosis. Manuscripts from these
studies, published in 2006–2013, document the impor-
tance of patient characteristics in evaluating patient
QOL7 and treatment decision making,8,9 factors that
inﬂuence treatment decisions,10 and the impact of race
and residence on these decisions.9 Other studies eluci-
dated patient experiences with second opinions,11 QOL
at 12 months of follow-up,12 use of complementary and
alternative medicine,13 and racial differences in
treatment-based beliefs and coping.14 Additional studies
explored physician–caregiver interactions15 and care-
giver roles16 in the decision process, as well as caregiver
burden.17–19 Studies also examined the process of build-
ing a collaborative study team20 and the agreement of
data ascertained from multiple sources.21
The predominant ﬁnding was that men diagnosed
with low-grade tumors, who would likely die from other
causes before disease progression, almost always opted
for active treatment regimens. Many of the men who
chose curative treatment were likely candidates for an AS
protocol where low-risk prostate cancer is closely moni-
tored but not treated immediately. AS allows men to
avoid the potential side effects of radiation and surgery
(e.g., urinary incontinence, impotence), reduces risk of
treatment of small indolent cancers, and has minimal
effect on QOL.22 Patients may opt for active treatment at
any time, or physicians can intervene if the tumor proﬁle
worsens. Data showed that 79% of men considering AS
reported a physician recommendation.9 These ﬁndings
highlighted the need for further examination of factors
associated with recommending, accepting, and partici-
pating in an AS protocol. This article reviews CDC-
supported work in prostate cancer and describes the
evolution of its research agenda.
Focus on Active Surveillance
State of the Science Conference
In 2009, building on ﬁndings from QOL research, CDC
initiated discussions with the Ofﬁce of Medical Applica-
tions Research, NIH, and the National Cancer Institute to
discuss interest in convening a State of the Science (SOS)
conference to assess the availability of published evidence
to distinguish patients who may be good candidates for
AS. Subsequently, the Ofﬁce of Medical Applications
Research entered into partnership with CDC, the
National Cancer Institute, and the American Cancer
Society to outline an agenda for the conference. Throughreview of the literature,23 clinical proﬁles, and tumor and
behavioral characteristics presented by leaders in the
ﬁeld, the conference panel was charged with synthesizing
the state of current knowledge, identifying gaps in
knowledge, and articulating a research agenda.
The NIH SOS Conference: Role of Active Surveillance
in the Management of Men with Localized Prostate
Cancer was held December 2011. A monograph of
conference proceedings24 summarized all evidence pre-
sented at the conference along with a reprint of the panel
consensus statement. The panel concluded that there was
not sufﬁcient evidence to allow deﬁnitive determination
of the optimal characteristics of prime AS candidates, but
that research needs be conducted to allow physicians and
researchers to identify men appropriately.25 Such an AS
research agenda needs to1. determine which men are the most appropriate
candidates;2. determine what is the optimal protocol for
surveillance;3. determine how to best communicate AS as an option
to patients;4. develop methods to assist patient decision making;
5. clarify patient reasons for accepting or rejecting AS as
a treatment strategy; and
6. conduct multicenter studies that incorporate com-
munity settings and partners.
The SOS conference concluded that AS be offered
more frequently to more patients with low-risk prostate
cancer.25 These recommendations can be used to gen-
erate discussion among physicians about greater use of
AS among patients with low-risk tumor proﬁles, foster
research that assists in better characterizing optimal
candidates for AS, and assist in the development of
decision aids that present AS with similar weight and
detail as active treatments.
Assessment of Patient Perceptions of Active
Surveillance
Testimony presented during the SOS conference high-
lighted qualitative research that compared AS, surgery,
and radiation therapy.26 Results showed that information
about treatment options can be presented such that men
accepted AS as an option in relation to the major
treatments26; however, no literature speciﬁcally asked
patients and caregivers what types of information their
physicians needed to provide to make AS an equally
viable option to active treatment.
In 2009, concomitant with SOS planning talks, CDC
funded two Prevention Research Centers (University of
Texas Health Science Center at Houston and Emorywww.ajpmonline.org
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perspective, desired talking points and preferred content
about AS. These studies could provide the basis for
developing an educational intervention for physician
discussion with patients about AS and the preferred
patient content to include in conversations that would
aid in making AS an acceptable alternative.Study 1: Acceptability of Active Surveillance as a
Treatment Choice for Prostate Cancer Among U.S.
Men
The University of Texas Health Science Center at
Houston assembled convenience samples of African
American, Hispanic, and non-Hispanic white men
recruited from Houston and El Paso, aged 40–70 years,
who had a prostate-speciﬁc antigen test within the
previous 2 years, and no history of prostate cancer.27
Men and identiﬁed caregivers participated in a series of
focus groups segmented by gender; race/ethnicity; and
language (English, Spanish), conducted between May
2010 and February 2011. Groups discussed how partic-
ipants would make treatment decisions if they (or their
partners) were diagnosed with early-stage localized
prostate cancer, what information would be needed to
make an informed decision, how they would evaluate
information, and who they would involve in the decision-
making process.27 Additionally, following a separate
recruitment of newly diagnosed patients, 15 men who
selected AS and 15 men treated with surgery or radiation
participated in telephone interviews about discussed and
considered treatment options, patient descriptions of AS,
how the decision was made, physician recommendations,
and their partner’s role in decision making.28Study 2: Active Surveillance Attitudes and
Perceptions: Decision Making by Men and Their
Signiﬁcant Others for Early-Stage Prostate Cancer
Emory University’s AS Attitudes and Perceptions study,
conducted from September 2009 through September
2012, utilized a multicenter, mixed-methods design,
combining both qualitative and quantitative method-
ologies to assess factors men and their caregivers regard
as vital to informed decision making about prostate
cancer therapies. Separate patient (n¼214) and caregiver
(n¼188) focus groups were held across six locations.29
Results from the above studies suggested that infor-
mation about the nature of prostate cancer, available
options, the beneﬁts and harms of the options, and their
likelihood of occurrence should be included in decision
aids to assist patients in their discussions with providers
and expressing their outcome preferences. Decision aids
should also offer prompts for questions to doctors andDecember 2015messages designed to reinforce the importance of sharing
one’s preferences.27 Men who made treatment decisions
displayed receptiveness to AS when fully informed about
this option,28 and described it as an organized process
with a rigorous and reassuring protocol of periodic
testing, with potential for subsequent and timely decision
making about any future treatment, and as an option for
prolonging good health and function. Rationales for
choosing AS included “buying time” without experienc-
ing adverse effects of treatment, waiting for better treat-
ments, trusting their physician’s monitoring, and
perceiving their cancer as very low risk.28 The AS
Attitudes and Perceptions study revealed that men were
more concerned about treatment side effects whereas
caregivers were more interested in a treatment’s potential
to increase survival and preferred that primary care
providers (versus urologists or radiologists) should dis-
cuss all prostate cancer options with patients (partic-
ularly AS), as primary care providers were perceived as
neutral advocates for patients.30Lessons Learned
CDC-supported work revealed that the majority of men
newly diagnosed with prostate cancer opt for surgery or
radiation. The SOS conference panel recommended that
AS be offered to more men. Information was needed to
help patients and caregivers in their consideration of AS.
The conference garnered insights into how to initiate
discussions with patients about AS and elicited patient
and caregiver concerns regarding AS and other treatment
choices. Patients taught that being well informed about
AS facilitates acceptability and that some men prefer to
have such discussions with primary care physicians.Putting It Together
Future CDC research may include investigations about
the various components of the AS conversations, meth-
ods to support patient treatment decision making, and
ensuring that all patients are informed and educated
about all of their treatment options. Additional studies
may explore barriers and facilitators of AS as a viable
treatment option and ensure that it is presented to
appropriate patients with the same emphasis as active
treatments. Consistent with the SOS agenda to develop
methods to assist patient decision making, CDC sought
to explore the design of a treatment decision aid with a
substantial AS component that would acknowledge
sociodemographic and cultural differences, attend to
patient informational needs and consider patient desired
goals and outcomes, facilitate collaborative involvement
of both the patient and caregiver in the decision process,
and address the role of the provider. AS is frequently
Hall and Lee Smith / Am J Prev Med 2015;49(6S5):S483–S488S486given little attention in decision aids, and an effective
decision aid could provide more-complete and accurate
descriptions of this option and represent it as an appro-
priate strategy for men with low-risk localized prostate
cancer who are concerned about aggressive treatment
complications.31 Decision aids should also meet quality
standards for content, development processes, and effec-
tiveness—demonstrating their ability to increase knowl-
edge about treatment options and improve harmony
between patient values and the selected treatment.32
Study 1: Development and Evaluation of an
Interactive Clinical Decision Dashboard to Support
Treatment Decisions for Men With Low-Grade,
Local-Stage Prostate Cancer
In 2014, CDC funded the University of Rochester to develop
and test an interactive multimedia decision aid in the form
of a clinical decision dashboard,33 designed to improve the
quality of clinical decision making for initial treatment of
patients with newly diagnosed, low-risk prostate cancer. The
tool will be designed to allow for multiple considerations
(tumor characteristic, patient preferences, caregiver input)
during decision-making deliberations with the goals of1. informing recently diagnosed men of their treatment
options, including AS, and helping them to determine
their treatment preferences; and2. supporting providers by providing up-to-date infor-
mation summaries about treatment outcomes tailored
for individual patient demographics and tumor
characteristics.
A clinical trial will be conducted to compare the effects
of the prostate decision dashboard versus usual care on
patient knowledge regarding the management and treat-
ment options available, measures of the decision-making
process including decisional conﬂict and shared
decision-making process, the selected treatments, and
6- and 12-month outcome assessments of clinical status,
decisional regret, and cancer-related QOL.
Impact of CDC Research Agenda
Since 2003, CDC has engaged in a prostate cancer public
health research agenda that has informed understanding
of the needs and experiences of survivors of localized
prostate cancer. This research has identiﬁed the following
priorities for public health:1. engaging in education to effectively inform patients and
caregivers about the various available treatments and
support the decision-making process, particularly among
men who are traditionally medically underserved;2. providing decision tools for patients, caregivers, and
providers to promote effective conversation about all
treatment options, including AS;3. engaging in regular surveillance and evaluation of AS
uptake, including sociodemographic, QOL, and clin-
ical measures;4. reducing loss to follow-up of men on AS protocols; and
5. tracking and evaluating decisions to terminate an AS
protocol, including clinical status and QOL outcomes
pre– and post–active treatment.
In the 4 years since the SOS conference, use of AS for
patient management has grown in popularity,34,35 and
research has proliferated in a number of areas, including
better characterization of suitable AS candidates,36,37
deﬁning appropriate standardized AS protocols,38 risks
associated with monitoring,39 and criteria for disease
progression.40 Recent studies have reviewed the quality of
care received by patients undergoing AS,41 and new tools
to safely monitor low-risk prostate cancer42,43 are being
proposed, such as use of biomarkers to better stratify risk
of disease progression.44–46 New studies are beginning to
quantify the number of men who are lost to follow-up
while on AS protocols.47 Overall knowledge of who needs
to be offered AS and how to monitor them has improved.
Future research may more explicitly characterize an
appropriate AS protocol for African American men.
Recent literature suggests that the tumors of African
American men on AS initially characterized as low risk
are often upgraded on serial biopsy,48 have worse
pathologic characteristics,49 and that disease is more
likely to recur following surgery50 compared with men of
other races, although these results have not been con-
ﬁrmed in other studies.51 These ﬁndings have raised the
question of whether AS is appropriate for African
American men, if this group requires more-stringent
surveillance strategies, or whether more extensive initial
clinical indicators to determine eligibility for AS are
warranted. Methods to effectively determine the potential
aggressiveness of small tumors and the exact protocols
for monitoring all men are needed.
CDC’s early prostate cancer work highlighted that
poor physician communication was associated with men
not making a treatment choice, especially among African
American men.9 Education about active treatments, AS,
potential for complications and recurrence, physical side
effects, and impact on QOL is still needed by all decision
makers to inform choices made by men and their
caregivers.52 CDC-funded work has served as a model
for assessing the perspectives of patient, caregiver, and
physician, promoting discussion of AS, and developing
tools to assist patient–physician conversations. Improving
the quality of survivorship among men diagnosed withwww.ajpmonline.org
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patients for certain treatments, improving patient knowl-
edge and awareness about treatment choices, and under-
standing the impact and roles of providers and caregivers
in treatment decision making. CDC and its partners
remain committed to exploring aspects of prostate cancer
treatment decision making that present opportunities to
improve cancer survivorship, reduce overtreatment, and
enhance QOL of patients and caregivers.
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